This summary was created by AI, based on 2 opinions in the last 12 months.
Based on the reviews, it appears that Catalent (CTLT-N) is currently facing financial problems, causing experts to advise staying away from this stock for the time being. There is also talk of potential acquisition by Danaher or Illumina, but until a decision is made, experts recommend against buying this stock.
Danaher (he owns) or Illumina could buy CTLT, at least that's the talk. Until something happens, he won't buy this.
They make the tools that helped Moderna make the Covid vaccine. Roared during the pandemic, then crashed in 2022, but is soaring now. Rumoured that Danaher could take this over.
Catalent is a American stock, trading under the symbol CTLT-N on the New York Stock Exchange (CTLT). It is usually referred to as NYSE:CTLT or CTLT-N
In the last year, 2 stock analysts published opinions about CTLT-N. 0 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Catalent.
Catalent was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Catalent.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Catalent In the last year. It is a trending stock that is worth watching.
On 2024-03-18, Catalent (CTLT-N) stock closed at a price of $55.96.
They had a financial problem. Stay away for a while.